Gene expression profiling of sarcoma cells treated with mithramycin A (MTA), nano-encapsulated MTA or MTA-analogs

This study was designed to gain insight about the mechanisms involved in the anti-tumor effects of mithramycin A (MTA) and the MTA analog EC-8042 in sarcoma cells. In addition, we also studied whether this molecular features could be influenced by the nano-encapsulation of MTA. Overall design: we have performed RNA seq analyses in myxoid liposarcoma T-5H-FC#1 cells treated in triplicate with either DMSO (control), or the IC50 values of free MTA (M_F) (25 nM), MTA loaded in polymeric PLG-nanoparticles (M_NP) (25 nM) or EC-8042 (300 nM) for 24 hours. In addition, this study includes RNA seq analyses of 143B osteosarcoma cells treated with DMSO (control) or the IC50 values of EC-8042 (100 nM) for 24 hours.

本研究旨在阐明光神霉素A（mithramycin A, MTA）及其类似物EC-8042在肉瘤细胞中发挥抗肿瘤作用的分子机制。此外，本研究同时探讨了MTA的纳米包封是否会对相关分子特征产生影响。
实验设计概述：我们对黏液样脂肪肉瘤T-5H-FC#1细胞进行了RNA测序（RNA-seq）分析，该细胞分别以二甲基亚砜（dimethyl sulfoxide, DMSO，对照组）、游离型MTA（M_F，半最大效应浓度IC₅₀为25 nM）、负载于聚乳酸-羟基乙酸共聚物（PLG）纳米颗粒的MTA（M_NP，半最大效应浓度IC₅₀为25 nM）或EC-8042（半最大效应浓度IC₅₀为300 nM）处理，并设置三次生物学重复，处理时长均为24小时。此外，本研究还包含对143B骨肉瘤细胞的RNA测序分析，该细胞分别以二甲基亚砜（对照组）或EC-8042（半最大效应浓度IC₅₀为100 nM）处理，处理时长为24小时。